Beyond Air sells a hospital breathing-therapy system that makes a key treatment on demand, and new purchasing access and overseas partners could put it in front of far more hospitals sooner than many expect. The catch is it leans heavily on one product while still burning cash, so slower adoption, tougher competition, or pricing pressure could quickly change the story.Read more
Beyond Air is pushing its LungFit respiratory device into more hospitals worldwide through new partners and big U.S. buying networks, aiming to turn early traction into steadier, repeat business. The catch is it’s still burning cash and depends heavily on this one platform, so any product delays or slower adoption could force more fundraising and slow the story.Read more
Key Takeaways Slow onboarding in hospitals and regulatory hurdles may significantly restrict revenue growth and the ability to capitalize on expanding market access. Heavy reliance on a single core product and growing competition from advanced medtech firms increase both revenue concentration risk and margin pressure.Read more
No trending discussion available.
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
